Cyclerion Therapeutics, Inc.
CYCN
$2.76
$0.2158.45%
NASDAQ
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 14.81% | -95.51% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 14.81% | -95.51% | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -54.32% | -95.51% | |||
| SG&A Expenses | 13.78% | 20.35% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 14.76% | 17.94% | |||
| Operating Income | -14.76% | -390.24% | |||
| Income Before Tax | 77.33% | -369.62% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 77.33% | -369.62% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 77.33% | -369.62% | |||
| EBIT | -14.76% | -390.24% | |||
| EBITDA | -- | -- | |||
| EPS Basic | 81.13% | -368.15% | |||
| Normalized Basic EPS | 4.41% | -368.15% | |||
| EPS Diluted | 81.13% | -368.15% | |||
| Normalized Diluted EPS | 4.41% | -368.15% | |||
| Average Basic Shares Outstanding | 20.15% | 0.55% | |||
| Average Diluted Shares Outstanding | 20.15% | 0.55% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||